BioSpace News Archive

KARL STORZ Endoscopy-America, Inc., a leader in minimally invasive surgical technology and related medical systems, announces the latest advancement in endoscopic imaging.

Southwest Research Institute has expanded its capability to evaluate internal combustion engine aftertreatment catalysts, integrating an existing SwRI technology with a mass spectrometer.

Henry Schein, Inc., the world’s largest provider of health care solutions to office-based dental and medical practitioners, announced the acquisition of a majority ownership position in Prism Medical Products, LLC, a nationwide provider of specialty home medical supplies with a core competency in advanced wound care products.

Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious blood diseases, announced today that company management will participate in two upcoming investor conferences in January:

One of the recent developments in the biotechnology market comprises the development of a promising solution to the problem of unwanted genetic changes associated with CRISPR-Cas9.

A notable uptick in bioterrorism attack is slated to boost biodefense market size following the influence of biological agents, including Ebola, anthrax, fever viruses, smallpox, and plague.

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix, will present at four upcoming virtual conferences in January.

Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that Paul Gudonis, the Company’s chief executive officer, and David Henry, chief financial officer, will present at the H.C. Wainwright Virtual BioConnect 2021 Conference

Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough, Ph.D., President and Chief Executive Officer, will participate in two events at the H.C. Wainwright Virtual BioConnect Conference taking place Jan. 11-14, 2021.

NeoGenomics, Inc. (NASDAQ:NEO) a leading provider of cancer-focused genetics testing services and global oncology contract research services, today announced that it has commenced proposed underwritten public offerings of approximately $200,000,000 of newly issued shares of common stock and $250,000,000 aggregate principal amount of convertible senior notes due 2028